- Home
- DNLI
as 02-21-2025 12:35pm EST
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 3.1B | IPO Year: | 2017 |
| Target Price: | $37.91 | AVG Volume (30 days): | 824.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.73 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.56 - $33.33 | Next Earning Date: | 03-04-2025 |
| Revenue: | N/A | Revenue Growth: | 204.74% |
| Revenue Growth (this year): | -97.32% | Revenue Growth (next year): | 289.18% |
Stock Insider Trading Activity of Denali Therapeutics Inc. (DNLI)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Krognes Steve E. | DNLI | Director | Jan 7 '25 | Sell | $20.81 | 3,339 | $69,484.59 | 25,757 | |
| Watts Ryan J. | DNLI | President and CEO | Jan 6 '25 | Sell | $20.52 | 36,916 | $750,955.02 | 260,721 | |
| Schuth Alexander O. | DNLI | COFO and Secretary | Jan 6 '25 | Sell | $20.52 | 15,162 | $308,290.77 | 247,215 | |
| Ho Carole | DNLI | Chief Medical Officer | Jan 6 '25 | Sell | $20.52 | 15,162 | $308,290.77 | 178,580 | |
| SATO VICKI L | DNLI | Director | Jan 2 '25 | Sell | $20.91 | 3,080 | $64,402.80 | 107,976 | |
| Krognes Steve E. | DNLI | Director | Dec 31 '24 | Sell | $20.25 | 30,000 | $607,500.00 | 25,757 |
Latest Denali Therapeutics Inc. News
DNLI Breaking Stock News: Dive into DNLI Ticker-Specific Updates for Smart Investing
MT Newswires
10 days ago
Deutsche Bank Initiates Coverage on Denali Therapeutics With Buy Rating, $31 Price Target
Zacks
14 days ago
DNLI Reports Upbeat Longer-Term Data From Hunter Syndrome Study
GlobeNewswire
15 days ago
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa
GlobeNewswire
22 days ago
Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™
Zacks
a month ago
Denali Gains 26.6% in a Year: How Should You Play the Stock?
Insider Monkey
a month ago
Why Denali Therapeutics (DNLI) Is the Biotech Stock with Biggest Upside Potential
GlobeNewswire
a month ago
Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
Zacks
a month ago
DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation
Compare DNLI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DNLI Denali Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.